Hello, Guest!

Welcome to MS Money Moves!

Biotech stock research & education made easy!

Don’t miss out on
our next 100%+ pick & time savings!

How It Works

MS gives you an edge over other investors through our comprehensive insights in biotech stocks delivered via SMS, Email & our website.
The days of needing a Ph.D & taking weeks to research investments is over! 
*We have a team standing by to help answer subscribers questions!
*Subscribers portfolio following our service

What Our Subscribers Say About US


The MS executive team has extensive experience between them and complimentary skill sets gained through actively investing in the biotech industry. Over the years they have developed a strategy and fine-tuned research methods, yielding returns that have proven to outpace the market and many analysts. 

Zion Miller

CEO & Co Founder

Sultan Beardsley

COO & Co Founder

Chris Stang


Michael Lipari


Travis Kellerman



Updated Every Night!

PT= Price target (i.e our approximate exit price)Unless stated otherwise, the price next to the ticker is a suitable entry price. Let us know if you are not receiving SMS text alerts (info@msmoneymoves.com) Let us know if you have any comments or feedback regarding the format of Trade Insights.
LJPC & BCRX Updates: 5/27/20

May 27, 2020 by Sultan Beardsley

In a matter of months, a novel strain of coronavirus infamously known as COVID-19 has spiraled from a local outbreak in China into a global pandemic. To date, there have been 1.5M+ confirmed cases and 88.3K deaths worldwide. The epicenter has shifted in a short period of time from Wuhan China, to Milan Italy, and most recently, to our own backyard in New York City.

Reader's Choice; New Institutional Buys 1Q2020

May 30th, by Chris Stang

Here at MS Money Moves, we seek to provide the research edge that retail investors need in order to be successful in these volatile markets. One thing we know in the world of investing in biotechnology is that nothing is certain. We firmly believe that strong, sound fundamentals are an essential aspect of a biotechnology company. Then, we look at other aspects of companies, such as institutional investors and upcoming catalysts. Now that we have touched upon this oversimplified approach to investing, let’s take a look at some new research and Intel.


MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.

The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.